)
Vanda Pharmaceuticals (VNDA) investor relations material
Vanda Pharmaceuticals Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Portfolio and financial outlook
Five approved products: Fanapt, BYSANTI, HETLIOZ, PONVORY and NEREUS; four are marketed, with BYSANTI launch expected by year-end.
Imsidolimab is under FDA review for GPP, with a Dec. 12 PDUFA date and potential sixth product approval by year-end.
Q3 revenue was ~$70M, up 24% YoY and 38% sequentially; operating expenses were ~$93M, down ~18% sequentially; cash was $140M.
Expenses are expected to moderate as clinical, launch-infrastructure and supply investments conclude; cash is expected to fund operations through at least end-2027.
BYSANTI and psychiatry growth
Revenue goal by 2030 is $1B, including $750M from psychiatry and $250M from other products.
Fanapt revenue is expected at $140M-$160M for the year; it is expected to go generic in Nov. 2027, while BYSANTI net price is expected to be about 2x Fanapt’s.
BYSANTI launch is expected by year-end, initially using Fanapt’s commercial resources; longer term, promotion is expected to shift toward BYSANTI.
BYSANTI MDD Phase III readout is expected in H1 2027; positive data could support an sNDA based on one Phase III study, with a label expansion potentially in 2028.
MDD represents an estimated 20M additional potential patients versus ~10M for current indications; DTC promotion could be considered if the label expands.
NEREUS opportunity
Launched for motion sickness in May; ~70M U.S. people are affected and more than 10M seek treatment. Promotional campaigns have generated website traffic, opt-ins and prescriptions.
Motion-sickness WAC is $255 per pill and cash price is $85; growth is expected to be steady and deliberate as promotional efficiency is refined.
In a Phase II Wegovy trial, vomiting occurred in 60% of placebo patients versus ~30% with NEREUS; Phase III confirmed a significant reduction, with greater effects among patients with more severe vomiting.
FDA discussions and an sNDA are planned; a GLP-1 vomiting label could be possible as early as 2028. Trial use was 14 days around a Wegovy dose, with potential use at initiation, dose escalation or restart.
- Bysanti’s launch and potential MDD label expansion are key to extending the psychiatry franchise.VNDA
Stifel 2026 Healthcare Conference 2026 - Five approved brands anchor a portfolio targeting near-term launches and pipeline catalysts.VNDA
Corporate presentation - Q3 revenue grew 24% as costs eased, but HETLIOZ generic pressure and higher 2026 cash burn persist.VNDA
Q3 2026 - BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead.VNDA
H.C. Wainwright 28th Annual Global Investment Conference - BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth.VNDA
12th Annual Cantor Fitzgerald Global Healthcare Conference - Fanapt® growth and new launches offset HETLIOZ® declines, shaping a strong 2026 outlook.VNDA
Q2 2026 - Fanapt and milsaperidone drive growth, with up to six products targeted by 2026.VNDA
Cantor Global Healthcare Conference 2025 - Directors elected, auditor ratified, and all proposals approved with no shareholder questions.VNDA
AGM 2026 - Q1 2025 revenue up 5%, Fanapt surges, but net loss widens on R&D and licensing costs.VNDA
Q1 2025
)
)
)
)
)
)
)
)